

SS ISO 11135 : 2019
ISO 11135:2014+A1:2018, IDT
(ICS 11.080.01)

SINGAPORE STANDARD

**Sterilisation of health-care products – Ethylene
oxide – Requirements for the development,
validation and routine control of a sterilisation
process for medical devices**

SS ISO 11135 : 2019

ISO 11135:2014+A1:2018, IDT
(ICS 11.080.01)

SINGAPORE STANDARD

**Sterilisation of health-care products – Ethylene
oxide – Requirements for the development,
validation and routine control of a sterilisation
process for medical devices**

Published by Enterprise Singapore

All rights reserved. Unless otherwise specified, no part of this Singapore Standard may be reproduced or utilised in any form or by any means, electronic or mechanical, including photocopying and microfilming, without permission in writing from Enterprise Singapore. Request for permission can be sent to: standards@enterprisesg.gov.sg.

© ISO 2014 – All rights reserved
© Enterprise Singapore 2019

ISBN 978-981-48-3594-7

The content of this Singapore Standard was approved on 30 August 2019 by the Biomedical and Health Standards Committee (BHSC) under the purview of the Singapore Standards Council.

First published, 2020

BHSC consists of the following members:

	Name	Representation
Chairman	: Dr Yong Chern Chet	<i>Individual Capacity</i>
Deputy Chairmen	: Mr Vincent Cheung	<i>Individual Capacity</i>
	Ms Selina Seah	<i>Changi General Hospital</i>
	Ms Wong Woei Jiuang	<i>Health Sciences Authority</i>
Advisor	: Ms Jacqueline Monteiro	<i>Individual Capacity</i>
Secretary	: Mr Kevin Tan	<i>Singapore Manufacturing Federation – Standards Development Organisation</i>
Members	: Mr Alec Chow Boon Kuan	<i>Medtronic International Ltd</i>
	Mr Chung Kwong Yuew	<i>Temasek Polytechnic (BioMedical Engineering Faculty)</i>
	Ms Heidi Goh	<i>Singapore Manufacturing Federation (Medical Technology Industry Group)</i>
	Prof James Goh	<i>Biomedical Engineering Society (Singapore)</i>
	Dr Lai Choon Sheen	<i>Eu Yan Sang International Ltd</i>
	Dr Christopher Lam	<i>Health Sciences Authority</i>
	Assoc Prof Leo Hwa Liang	<i>National University of Singapore</i>
	Dr Lin Jianhua	<i>TÜV SÜD PSB Pte Ltd</i>
	Dr Leonard Loh	<i>Nanyang Polytechnic</i>
	Ms Audrey Lok	<i>Enterprise Singapore</i>
	Assoc Prof Eddie Ng Yin Kwee	<i>Nanyang Technological University</i>
	Dr Ong Siew Hwa	<i>Acumen Research Laboratories Pte Ltd</i>
	Dr Padmanabhan Saravanan	<i>Temasek Polytechnic (Centre of Innovation for Complementary Health Products)</i>
	Mr Peh Ruey Feng	<i>Advent Access Pte Ltd</i>
	Prof Tan Puay Hoon	<i>Singapore Health Services Pte Ltd</i>
	Ms Wang Dan	<i>Biosensors International Group</i>
	Dr Sidney Yee	<i>Diagnostics Development (DxD) Hub</i>
	Dr Zhou Zhihong	<i>Singapore Bioimaging Consortium</i>

BHSC sets up the Technical Committee on Quality Management Systems to oversee the preparation of this standard. The Technical Committee consists of the following members:

	Name	Representation
Chairman	: Ms Heidi Goh	<i>Individual Capacity</i>
Secretary	: Mr Kevin Tan	<i>Singapore Manufacturing Federation – Standards Development Organisation</i>
Members	: Ms Jasmine Chan	<i>Konica Minolta Business Solutions Asia Pte Ltd</i>
	Ms Shiirlyn Ee	<i>Illumina</i>
	Ms Katherine Goh	<i>Singapore Accreditation Council</i>
	Dr Christopher Lam	<i>Health Sciences Authority</i>
	Mr Ng Chee Kai	<i>Becton Dickinson Medical Products Pte Ltd</i>
	Mr Ariq Tan	<i>Sivantos</i>
	Ms Grace Tan	<i>Edward Lifesciences (Singapore) Pte Ltd</i>
	Ms Diana Teo	<i>Medtronic International Ltd</i>
	Ms Wang Dan	<i>Biosensors International Group</i>
	Ms Zhu Huifang	<i>Smith & Nephew Pte Ltd</i>

The Technical Committee sets up the National Mirror Working Group on ISO/TC 210 to prepare this standard. The Working Group consists of the following experts who contribute in their *individual capacity*:

	Name
Convenor	: Dr Margam Chandrasekaran
Secretary	: Mr She Long Huai
Members	: Ms Heidi Goh
	Ms How Pei Sin
	Mr Liew Ee Bin
	Mr Jason Lim
	Mr Narayanan Sethu
	Mr Caleb Ng
	Mr Paul Tan

The organisations in which the experts of the National Mirror Working Group are involved are:

Access-2-Healthcare

BioPharmaSpec UK Ltd

Edwards Lifesciences (Singapore) Pte Ltd

Sanmina Corporation Singapore

Singapore Manufacturing Federation (Medical Technology Industry Group)

Stendard

SystemED Pte Ltd

TÜV SÜD PSB Pte Ltd

Wise Consultants and Services Pte Ltd

Contents

	Page
National Foreword	7
Foreword	8
Introduction	9
1 Scope	11
1.1 Inclusions	11
1.2 Exclusions	11
2 Normative references	12
3 Terms and definitions	13
4 Quality management systems	22
4.1 Documentation.....	22
4.2 Management responsibility	22
4.3 Product realization.....	22
4.4 Measurement, analysis and improvement — Control of nonconforming product.....	23
5 Sterilizing agent characterization	23
5.1 General	23
5.2 Sterilizing agent.....	23
5.3 Microbicidal effectiveness.....	23
5.4 Material effects.....	23
5.5 Safety and the environment	23
6 Process and equipment characterization	24
6.1 General	24
6.2 Process characterization.....	24
6.3 Equipment characterization.....	25
7 Product definition	26
7.1 General	26
7.2 Product safety, quality and performance.....	26
7.3 Microbiological quality	27
7.4 Documentation.....	27
8 Process definition	27
9 Validation	28
9.1 General	28
9.2 Installation qualification, IQ	29
9.3 Operational qualification, OQ.....	29
9.4 Performance qualification, PQ.....	30
9.5 Review and approval of validation	32
10 Routine monitoring and control	34
11 Product release from sterilization	35
12 Maintaining process effectiveness	36
12.1 General.....	36
12.2 Maintenance of equipment.....	36
12.3 Requalification.....	37

12.4	Assessment of change.....	37
12.5	Assessment of equivalence.....	38
Annex A (normative) Determination of lethal rate of the sterilization process — Biological indicator/bioburden approach.....		
		39
Annex B (normative) Conservative determination of lethal rate of the sterilization process — Overkill approach.....		
		40
Annex C (informative) Temperature sensors, RH sensors and biological indicator numbers.....		
		42
Annex D (informative) Guidance on the application of the normative requirements		
		45
Annex E (normative) Single batch release		
		93
E.1	General.....	93
E.2	Procedure.....	93
Bibliography.....		96

National Foreword

This Singapore Standard was prepared by the National Mirror Working Group on ISO/TC 210 set up by the Technical Committee on Quality Management Systems under the purview of BHSC.

This standard is identical with ISO 11135:2014, “Sterilization of health-care products – Ethylene oxide – Requirements for the development, validation and routine control of a sterilization process for medical devices”, including its Amendment, published by the International Organization for Standardization.

NOTE 1 – Where appropriate, the words “International Standard” are read as “Singapore Standard”.

NOTE 2 – Reference to International Standards are replaced by applicable Singapore Standards/Technical References.

NOTE 3 – Where numerical values are expressed as decimals, the comma is read as a full point.

Attention is drawn to the possibility that some of the elements of this Singapore Standard may be the subject of patent rights. Enterprise Singapore shall not be held responsible for identifying any or all of such patent rights.

NOTE

- 1. Singapore Standards (SSs) and Technical References (TRs) are reviewed periodically to keep abreast of technical changes, technological developments and industry practices. The changes are documented through the issue of either amendments or revisions. Where SSs are deemed to be stable, i.e. no foreseeable changes in them, they will be classified as “Mature Standards”. Mature Standards will not be subject to further review, unless there are requests to review such standards.*
- 2. An SS or TR is voluntary in nature except when it is made mandatory by a regulatory authority. It can also be cited in contracts making its application a business necessity. Users are advised to assess and determine whether the SS or TR is suitable for their intended use or purpose. If required, they should refer to the relevant professionals or experts for advice on the use of the document. Enterprise Singapore and the Singapore Standards Council shall not be liable for any damages whether directly or indirectly suffered by anyone or any organisation as a result of the use of any SS or TR. Although care has been taken to draft this standard, users are also advised to ensure that they apply the information after due diligence.*
- 3. Compliance with a SS or TR does not exempt users from any legal obligations.*

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2. www.iso.org/directives

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received. www.iso.org/patents

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation on the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the WTO principles in the Technical Barriers to Trade (TBT), see the following URL: [Foreword - Supplementary information](#)

The committee responsible for this document is ISO/TC 198, *Sterilization of health care products*.

ISO 11135:2014 cancels and replaces ISO 11135-1:2007 and ISO/TS 11135-2:2008, both of which have been technically revised and condensed into a single standard.

As a result of the amendment, the following changes have been made to Annex E:

- clarification on the application of the method i.e. for research and development of new product or for clinical trial product;
- clarification that data resulting from a single batch release study can be used to support a full validation study;
- clarification that temperature and relative humidity sensors should be used to establish conditions in the sterilization load during both the half cycle and the full cycle comprising a single batch release.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

Introduction

A sterile medical device is one that is free of viable microorganisms. Medical devices produced under standard manufacturing conditions in accordance with the requirements for quality management systems (see for example ISO 13485) might, prior to sterilization, have microorganisms on them, albeit in low numbers. Such medical devices are non-sterile. The purpose of sterilization is to inactivate the microbiological contaminants and thereby transform the non-sterile medical devices into sterile ones.

The kinetics of inactivation of a pure culture of microorganisms by physical and/or chemical agents used to sterilize medical devices can generally best be described by an exponential relationship between the numbers of microorganisms surviving and the extent of treatment with the ethylene oxide (EO); inevitably this means that there is always a finite probability that a microorganism might survive regardless of the extent of treatment applied. For a given treatment, the probability of survival is determined by the number and resistance of microorganisms and by the environment in which the organisms exist during treatment. It follows that the sterility of any one medical device in a population subjected to sterilization processing cannot be guaranteed and the sterility of a processed population is defined in terms of the probability of there being a viable microorganism present on a medical device.

ISO 11135 describes requirements that, if met, will provide an ethylene oxide sterilization process intended to sterilize medical devices, which has appropriate microbicidal activity. Furthermore, compliance with the requirements ensures that validations conducted following this International Standard will provide products that meet the defined requirements for sterile products with a high degree of confidence. The specification for this probability is a matter for regulatory authorities and can vary from country to country (see for example EN 556-1 and ANSI/AAMI ST67).

Generic requirements of the quality management systems for design and development, production, installation and servicing are given in ISO 9001 and particular requirements for quality management systems for medical device production are given in ISO 13485. The standards for quality management systems recognize that, for certain processes used in manufacturing or reprocessing, the effectiveness of the process cannot be fully verified by subsequent inspection and testing of the product. Sterilization is an example of such a process. For this reason, sterilization processes are validated for use, the performance of the sterilization process monitored routinely and the equipment maintained.

Exposure to a properly validated, accurately controlled sterilization process is not the only factor associated with the provision of reliable assurance that the product is sterile and, in this regard, suitable for its intended use. Attention is therefore given to a number of considerations including:

- the microbiological status of incoming raw materials and/or components;
- the validation and routine control of any cleaning and disinfection procedures used on the product;
- the control of the environment in which the product is manufactured or reprocessed, assembled and packaged;
- the control of equipment and processes;
- the control of personnel and their hygiene;
- the manner and materials in which the product is packaged;

- the conditions under which product is stored.

The type of contamination on a product to be sterilized varies and this impacts upon the effectiveness of a sterilization process. Products that have been used in a health care setting and are being presented for resterilization in accordance with the manufacturer's instructions (see ISO 17664) are a special case. There is the potential for such products to possess a wide range of contaminating microorganisms and residual inorganic and/or organic contamination in spite of the application of a cleaning process. Hence, it is important to pay particular attention to the validation and control of the cleaning and disinfection processes used during reprocessing. Mixed product loads are common in health care facilities with throughput volumes dictated by historical and predicted demand for sterile product.

The requirements are the normative parts of ISO 11135 with which compliance is claimed. The guidance given in the informative annexes is not normative and is not provided as a checklist for auditors. The guidance in Annex D provides explanations and methods that are regarded as being suitable means for complying with the requirements for industry and health care facilities.

The guidance, in Annex D, is intended for people who have a basic knowledge of the principles of EO sterilization. Methods other than those given in the guidance can be used if they are effective in achieving compliance with the requirements of ISO 11135.

The development, validation and routine control of a sterilization process comprises a number of discrete but interrelated activities; e.g. calibration, maintenance, product definition, process definition, installation qualification, operational qualification and performance qualification. While the activities required by ISO 11135 have been grouped together and are presented in a particular order, ISO 11135 does not require that the activities be performed in the order in which they are presented. The activities required are not necessarily sequential, as the programme of development and validation may be iterative. It is possible that performing these different activities will involve a number of separate individuals and/or organizations, each of whom undertakes one or more of these activities. This International Standard does not specify the particular individuals or organizations to carry out the activities.

It is important that patient safety be addressed by minimizing exposure to EO and its by-products during normal product use. ISO 10993-7 specifies limits for EO and ethylene chlorohydrin (ECH); however, no exposure limits are set for ethylene glycol (EG) because risk assessment indicates that when EO residues are controlled, it is unlikely that biologically significant residues of EG would be present.

Sterilisation of health-care products — Ethylene oxide — Requirements for the development, validation and routine control of a sterilisation process for medical devices

1 Scope

1.1 Inclusions

This International Standard specifies requirements for the development, validation and routine control of an ethylene oxide sterilization process for medical devices in both the industrial and health care facility settings, and it acknowledges the similarities and differences between the two applications.

NOTE 1 Among the similarities are the common need for quality systems, staff training, and proper safety measures. The major differences relate to the unique physical and organizational conditions in health care facilities, and to the initial condition of reusable medical devices being presented for sterilization.

NOTE 2 Health care facilities differ from medical device manufacturers in the physical design of processing areas, in the equipment used, and in the availability of personnel with adequate levels of training and experience. The primary function of the health care facility is to provide patient care; medical device reprocessing is just one of a myriad of activities that are performed to support that function.

NOTE 3 In terms of the initial condition of medical devices, medical device manufacturers generally sterilize large numbers of similar medical devices that have been produced from virgin material. Health care facilities, on the other hand, must handle and process both new medical devices and reusable medical devices of different descriptions and with varying levels of bioburden. They are therefore faced with the additional challenges of cleaning, evaluating, preparing and packaging a medical device prior to sterilization. In this International Standard, alternative approaches and guidance specific to health care facilities are identified as such.

NOTE 4 EO gas and its mixtures are effective sterilants that are primarily used for heat- and/or moisture-sensitive medical devices that cannot be moist heat sterilized.

NOTE 5 Although the scope of this International Standard is limited to medical devices, it specifies requirements and provides guidance that can be applicable to other health care products.

1.2 Exclusions

1.2.1 This International Standard does not specify requirements for the development, validation and routine control of a process for inactivating the causative agents of spongiform encephalopathies such as scrapie, bovine spongiform encephalopathy and Creutzfeldt-Jakob disease. Specific recommendations have been produced in particular countries for the processing of materials potentially contaminated with these agents.

NOTE See ISO 22442-1, ISO 22442-2 and ISO 22442-3.

1.2.2 This International Standard does not detail a specified requirement for designating a medical device as sterile.

NOTE Attention is drawn to national or regional requirements for designating medical devices as “sterile”. See for example EN 556-1 or ANSI/AAMI ST67.

1.2.3 This International Standard does not specify a quality management system for the control of all stages of production of medical devices.

NOTE The effective implementation of defined and documented procedures is necessary for the development, validation and routine control of a sterilization process for medical devices. Such procedures are commonly considered to be elements of a quality management system. It is not a requirement of this International Standard to have a full quality management system during manufacture or reprocessing. The necessary elements are normatively referenced at appropriate places in the text (see, in particular, Clause 4). Attention is drawn to the standards for quality management systems (see ISO 13485) that control all stages of production or reprocessing of medical devices. National and/or regional regulations for the provision of medical devices might require the implementation of a full quality management system and the assessment of that system by a third party.

1.2.4 This International Standard does not specify requirements for occupational safety associated with the design and operation of EO sterilization facilities.

NOTE 1 For further information on safety, see examples in the Bibliography. National or regional regulations may also exist.

NOTE 2 EO is toxic, flammable and explosive. Attention is drawn to the possible existence in some countries of regulations giving safety requirements for handling EO and for premises in which it is used.

1.2.5 This International Standard does not cover sterilization by injecting EO or mixtures containing EO directly into packages or a flexible chamber.

NOTE See ISO 14937 for these types of EO processes.

1.2.6 This International Standard does not cover analytical methods for determining levels of residual EO and/or its reaction products.

NOTE 1 For further information see ISO 10993-7.

NOTE 2 Attention is drawn to the possible existence of national or regional regulations specifying limits for the level of EO residues present on or in medical devices.

2 Normative references

The following documents, in whole or in part, are normatively referenced in this document and are indispensable for its application. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 10012, *Measurement management systems — Requirements for measurement processes and measuring equipment*

ISO 10993-7, *Biological evaluation of medical devices — Part 7: Ethylene oxide sterilization residuals*

ISO 11138-1:2006, *Sterilization of health care products — Biological indicators — Part 1: General requirements*

ISO 11138-2:2006, *Sterilization of health care products — Biological indicators — Part 2: Biological indicators for ethylene oxide sterilization processes*

ISO 11140-1, *Sterilization of health care products — Chemical indicators — Part 1: General requirements*

ISO 11737-1, *Sterilization of medical devices — Microbiological methods — Part 1: Determination of a population of microorganisms on products*

ISO 11737-2, *Sterilization of medical devices — Microbiological methods — Part 2: Tests of sterility performed in the definition, validation and maintenance of a sterilization process*

ISO 13485:2003/Cor 1:2009, *Medical devices — Quality management systems — Requirements for regulatory purposes — Technical Corrigendum 1*

ISO 11138-7: —¹⁾, *Sterilization of health care products — Biological indicators — Part 7: Guidance for the selection, use and interpretation of results*

NOTE 1) Under preparation